What can we learn from pathophysiology and therapeutic targetable pathways from all genetic causes and associations in PH?

我们能从肺动脉高压所有遗传病因和关联中学到什么病理生理学知识和治疗靶向途径?

阅读:2

Abstract

Pulmonary hypertension (PH) encompasses a group of conditions which ultimately lead to elevated pulmonary arterial pressure. PH is classified into five subgroups, of which Group 1 pulmonary arterial hypertension (PAH), is the most extensively studied. Numerous causal genes have been identified in PAH, most notably germline mutations in bone morphogenetic protein receptor type 2 (BMPR2) and the wider BMP pathway. Often when considering the genetics of PH, sporadic idiopathic and heritable PAH dominates the discussion. There are a number of reviews that elegantly describe the 'state of the art' in respect to group 1 PAH, however this focus misses the wider context of genetic conditions where PH is a feature, but outside of the framework of classical 'idiopathic or heritable' PAH. In addition to variants in genes within the TGF-β/BMP signaling pathway, genes which regulate ion channels, the extracellular matrix, inflammation, angiogenesis, and mitochondrial dysfunction have been shown to play a significant role in PH pathogenesis across different PH groups. In this review, we aim to cast the net wider to understand what we can learn from the spectrum of genetic conditions where PH is an acknowledged feature or complication, and what this tells us about the important cellular, molecular and systems physiology features that predispose to PH and consequently might be treatment targets.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。